MarginsXMarginsX
Home › Markets › Health Care › SVRA

Savara Inc. (SVRA)

SVRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.46
-3.77% on the day
Market cap
$985.1M
Small cap
Revenue · 2020
$257K
Prior year not contiguous
Net income · 2020
-$49.6M
-19305.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1160308/000095017022005045/0000950170-22-005045-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.

Profile

FieldValue
TickerSVRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001160308
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2020

LineValue
Revenue$257K
Net income-$49.6M
Operating income-$49.3M
Net margin-19305.4%
Operating margin-19182.9%
Revenue growthNo prior-year revenue to compare
Cash$22.9M
Total assets$97.7M
P/E (computed)Net income was not positive
P/S (computed)3833.0×

Warning signs

Cash runway
2.7 months
$29.8M cash at September 30, 2026
Share count, 1 year
+8.4%
2025-11-12 to 2026-11-09 · +63.0% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$2.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$29.8M cash; operating cash flow -$32.6M a quarter.Report 2026-09-30
Shares outstanding220,623,511 (2026-11-09); 203,467,845 a year earlier; 135,341,024 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorRSM US LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$43.0M-$42.5M$29.8M$30.2MNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$40.2M-$29.7M$41.8M$30.1MNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$37.3M-$33.0M$38.8M$30.1MNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$32.2M-$25.1M$33.2M$29.9MNeeds four quarters10-K 2026-03-13
Q3 2025
2025-09-30
Not filed-$29.6M-$22.5M$16.3M$29.8MNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$30.4M-$26.3M$17.4M$29.7MNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$26.6M-$27.2M$19.6M$29.5MNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
Not filed-$29.0M-$23.3M$15.1M$26.6MNeeds four quarters10-K 2026-03-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-10-30
Latest annual report10-K2026-03-13
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-06-08
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.9%
1 month-2.9%
3 months-12.0%
Year to date-23.1%
1 year+8.9%
From 52-week high-33.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JBIOJade Biosciences Inc.$15.34-4.99%$975.3M
MLTXMoonLake Immunotherapeutics$11.73-6.16%$998.3M
VSTMVerastem Inc.$7.70-5.87%$970.3M
CYRXCryoPort Inc.$19.80-0.45%$1.0B
SPTXSeaport Therapeutics Inc.$19.12-4.30%$1.0B
MTRIMentari Therapeutics Inc.$19.87+6.83%$1.0B
AKTSAktis Oncology Inc.$16.16-2.77%$901.7M
CRVSCorvus Pharmaceuticals Inc.$10.60-0.38%$894.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier